How do you decide between carboplatin vs not recommending adjuvant chemotherapy entirely for patients with resected NSCLC with relative or absolute contraindications to cisplatin?

While I am unaware of any study directly addressing this question (in the adjuvant setting), there is clearly a general preference for cisplatin in the curative setting, hence the question. Reworded - is carboplatin SO inferior to cisplatin that you wouldn't give four cycles of a carboplatin regimen...